Protavio Announces Winner of the Olink Proteomics Sample Testing Contest

Protavio Ltd is thrilled to announce the winner of our highly anticipated Olink Proteomics Sample Testing Contest. This unique contest was designed to celebrate the launch of our new multi-platform proteomic facility, showcasing our advanced capabilities in multiplex proteomics, powered by the innovative Olink® Explore 384 Inflammation Panel.

We invited the scientific community to participate in this exclusive offer, which provides a complimentary testing service for 20 human plasma or serum samples. This opportunity enables researchers to measure 368 proteins, using Olink Explore, offering a deep dive into the inflammatory processes with unparalleled precision.

After a rigorous review of numerous compelling project submissions, we are excited to declare Maria Grigoriou, a dedicated Postdoctoral Fellow at the Biomedical Research Foundation Academy of Athens, Greece, as the contest winner. Maria’s project stands out for its groundbreaking approach to understanding Systemic Lupus Erythematosus (SLE) and the potential impact of belimumab treatment on the disease’s molecular landscape.

About the Project

Maria’s project involves the investigation of whole blood RNA-seq in SLE patients at baseline, one-, and six-months post-treatment. The study aims to identify how molecular fingerprints of innate immunity could predict a robust clinical response to belimumab and explore the treatment’s effects on reducing SLE activity and flare risks.

With the support of Protavio’s Olink® Explore 384 Inflammation Panel, the project seeks to uncover insights into SLE inflammation, including the roles of IFNs, chemokines, cytokines, and potentially unknown factors influenced by belimumab treatment. The analysis will be enriched by comparing samples collected at different treatment stages, under the expert supervision of Prof Boumpas.

Future of Discovery

Protavio is proud to support Maria’s pioneering research, which aligns perfectly with our mission to advance scientific discovery through cutting-edge technologies and expertise in multiplex proteomics. We eagerly anticipate the insights that will emerge from this project, contributing valuable knowledge to the field of autoimmune diseases and therapeutic interventions. We extend our heartfelt congratulations to Maria and express our gratitude to all participants who shared their innovative projects with us. 

Stay tuned for updates on Maria’s project and further opportunities to engage with Protavio’s state-of-the-art proteomics services, combining the Olink and Luminex platforms. Together, we continue to push the boundaries of research, unlocking new possibilities for understanding and treating complex diseases.

Scroll to Top